Use of cfDNA in Monitoring and Guiding Treatment for Cervical Cancer
A Prospective Study on the Application of Low-Depth Circulating Free DNA Fragmentomics in Monitoring Recurrence and Guiding Therapy for Cervical Cancer
This is a prospective, single-center, observational cohort study that plans to enroll 100 women aged 18 years or older with histologically confirmed cervical cancer who are scheduled to receive radical surgery, radiotherapy, or systemic therapy. The study aims to establish and validate a low-depth cfDNA fragmentomics approach-including tumor fraction, fragment length distribution, and copy number variation-together with cfHPV-DNA testing for monitoring recurrence risk and predicting treatment response. Serial blood samples (10 mL per collection) will be obtained before initial treatment, 1-4 weeks after standardized treatment, at 3 and 6 months, and every 3 months thereafter until 2 years after treatment completion or until an endpoint event; fresh or paraffin-embedded tumor tissue will also be collected for whole-exome sequencing and multi-omics analysis. The study will not alter participants' routine clinical treatment. Research-related risks are mainly blood draw-related discomfort, bleeding, or bruising; risks from standard radiotherapy, chemotherapy, or immunotherapy are part of routine clinical care and are not introduced by this observational study. Privacy and confidentiality risks will be minimized through informed consent, secure data storage, restricted database access, and confidential handling of records. cfDNA testing will be provided free of charge, and appropriate compensation may be provided based on participation and time commitment. The study is funded by 3D Medicines (Shanghai) Co., Ltd.; conflict-of-interest, data/sample-sharing, and intellectual property arrangements will be disclosed and managed according to institutional requirements.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiesteder
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 100730
- Peking Union Medical College Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
This single-center prospective observational cohort will enroll 100 adult women aged ≥18 years with histologically confirmed cervical cancer (including squamous cell carcinoma, adenocarcinoma, and other subtypes) who are planned to receive radical treatment with surgery, radiotherapy, and/or systemic therapy and who can provide complete clinical and follow-up data. Participants will undergo serial blood and tumor tissue collection before and after standard treatment for low-depth cfDNA fragmentomics and cfHPV-DNA analysis. Patients with a history of other malignancies (except cured skin basal cell carcinoma), severe hepatic/renal insufficiency, coagulation disorders, active infection, pregnancy or breastfeeding, inability to cooperate with follow-up or sample collection, or prior systemic therapy for cervical cancer (except neoadjuvant therapy) will be excluded. Routine clinical treatment is not altered.
Beskrivelse
Inclusion Criteria:
- Female aged 18 years or older.
- Histologically confirmed cervical cancer, including squamous cell carcinoma, adenocarcinoma, and other subtypes.
- Planned to receive radical treatment, including surgery, radiotherapy, or chemotherapy.
- Voluntarily agrees to participate and signs the informed consent form.
- Able to provide complete clinical and follow-up information for the study.
Exclusion Criteria:
- A history of other malignancies (except cured tumors such as basal cell carcinoma of the skin).
- Severe hepatic or renal insufficiency, coagulation disorders, or active infection.
- Pregnancy or breastfeeding.
- Inability to cooperate with follow-up or sample collection.
- Prior systemic therapy for cervical cancer (except neoadjuvant therapy).
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Objective response rate
Tidsramme: From initiation of primary treatment through 2 years after completion of treatment or until an endpoint event (recurrence, progression, or death), whichever occurs first; final analysis at study completion.
|
From initiation of primary treatment through 2 years after completion of treatment or until an endpoint event (recurrence, progression, or death), whichever occurs first; final analysis at study completion.
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- K9926
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .